中生製藥(1177.HK)收漲12% 聯營的科興新冠疫苗獲多國使用
格隆匯2月23日丨中生製藥(1177.HK)今日大肆上漲,盤中最高漲15.95%報8.58港元,股價創去年10月以來新高,最終收漲12.03%報8.29港元,領漲恆指成分股,市值1564億港元。中生製藥聯營的科興新冠疫苗獲批附條件上市後,已先後運抵香港、墨西哥、菲律賓、泰國和哥倫比亞緊急使用,馬來西亞也已簽約購買。美銀最新報吿指出,所持股科興(Sinovac)利潤貢獻和疫苗資產被低估,指中生目前的估值尚未反映來自科興利潤貢獻,從商業化的角度來看,考慮其更早的發佈時間,更好的定價環境和制量,Sinovac的新冠疫苗應比Cansino等其他上市公司更使人放心。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.